Boehringer Ingelheim’s Dabigatran Demonstrates Non-Inferiority To Lovenox
This article was originally published in The Pink Sheet Daily
Executive Summary
The drug maker is in discussions with U.S. regulators regarding submission for venous thromboembolism, but has not released a filing timeline.